Litigation Details for Cephalon Inc. v. Apotex Corp. (D. Del. 2010)

« Back to Dashboard

Cephalon Inc. v. Apotex Corp. (D. Del. 2010)

Docket		Date Filed	2010-08-18
Court	District Court, D. Delaware	Date Terminated	2013-03-30
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	7,132,570; RE37,516
Link to Docket	External link to docket

Details for Cephalon Inc. v. Apotex Corp. (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-08-18				External link to document

Cephalon Inc. v. Apotex Corp. Litigation Summary: Nuvigil Patent Dispute, ANDA Challenge, and Generic Entry Risk

Last updated: October 3, 2026

Cephalon Inc. v. Apotex Corp., No. 1:10-cv-00695, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Apotex's abbreviated new drug application for generic Nuvigil, the brand formulation of armodafinil. Cephalon sued after receiving a Paragraph IV certification challenging patents listed for Nuvigil in the FDA Orange Book.

The case ended through settlement rather than a trial or merits judgment. Apotex obtained a defined future generic-entry opportunity, while Cephalon preserved commercial exclusivity for the settlement period. The docket did not produce a judicial ruling invalidating the asserted patents or holding them unenforceable.

What drug and regulatory filing were at issue in Cephalon v. Apotex?

The dispute involved Nuvigil, which contains armodafinil, the R-enantiomer of modafinil. Cephalon developed and marketed Nuvigil for excessive sleepiness associated with obstructive sleep apnea, shift-work sleep disorder, and narcolepsy.

Item	Detail
Brand drug	Nuvigil
Active ingredient	Armodafinil
Reference sponsor	Cephalon Inc.
Regulatory pathway	Abbreviated New Drug Application
Generic applicant	Apotex Corp.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:10-cv-00695
Case type	Hatch-Waxman patent infringement
Trigger	Apotex Paragraph IV patent certification
Resolution	Settlement and dismissal, without a merits adjudication

Apotex's ANDA sought approval for generic armodafinil tablets. Under the Hatch-Waxman framework, a Paragraph IV certification alleged that one or more Orange Book-listed patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Cephalon's lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the statutory exceptions.

What patents protected Nuvigil in the Apotex litigation?

The case is associated with Cephalon's Nuvigil patent estate, including patents directed to armodafinil compositions and related pharmaceutical claims. Public case materials identify U.S. Patent No. 6,848,327 as a central patent in the Nuvigil patent dispute. The broader Nuvigil Orange Book estate also included continuation and related patents that extended protection around dosage forms, compositions, and approved uses.

Patent family or category	Relevance to Nuvigil
U.S. Patent No. 6,848,327	Core armodafinil pharmaceutical-composition protection associated with Nuvigil
Related continuation patents	Additional composition and formulation claims
Method-of-use patents	Claims directed to treatment of excessive sleepiness and related conditions
Orange Book-listed patents	Created the basis for Paragraph IV certification and infringement litigation

The key analytical point is that an ANDA case does not require the brand company to prove every patent in its broader portfolio. The plaintiff typically asserts the patents implicated by the applicant's certification and the product description in the ANDA.

Patent scope mattered because a generic applicant could avoid infringement by designing around a formulation claim, but it could not avoid a method-of-use patent merely by changing the product label if the ANDA label retained the patented indication. Conversely, a product claim covering the active ingredient, particle characteristics, or pharmaceutical composition could create a more direct barrier to approval.

When did Nuvigil lose regulatory exclusivity?

Nuvigil received FDA approval on June 15, 2007. Its principal regulatory exclusivity period was shorter than the asserted patent term.

FDA milestone	Date or implication
Nuvigil approval	June 15, 2007
New chemical entity exclusivity	Not available because armodafinil is closely related to previously approved modafinil
Three-year clinical-investigation exclusivity	Generally ran from approval for the qualifying new indication or dosage form
Paragraph IV litigation	Filed after Apotex challenged listed patents
Generic approval constraint	Controlled primarily by the patent stay and settlement terms after regulatory exclusivity expired

Armodafinil did not receive the five-year new chemical entity exclusivity associated with a wholly new active moiety. The FDA treated armodafinil in the context of the prior approval of modafinil. As a result, the commercial defense relied principally on patent rights, not long-term NCE exclusivity.

The 2010 litigation occurred as Nuvigil's regulatory exclusivity position was becoming less significant. Cephalon therefore had a commercial incentive to enforce its patent estate and negotiate controlled generic-entry terms.

What was the litigation timeline in Cephalon v. Apotex?

Event	Timing
Apotex filed an ANDA for generic armodafinil	Before litigation
Apotex served a Paragraph IV certification	2010
Cephalon filed suit	2010
Civil action assigned	No. 1:10-cv-00695
Statutory FDA approval stay	Triggered by the infringement action
Settlement reached	During the litigation
Case dismissed	By stipulated court order
Merits trial or invalidity judgment	None

The litigation did not proceed to a public claim-construction ruling, bench trial, or appellate decision. The case's legal significance therefore rests on the settlement and its effect on generic-entry timing rather than on a judicial interpretation of the asserted patent claims.

Cephalon's Nuvigil disputes formed part of a wider set of patent and settlement negotiations involving generic applicants. The broader commercial context changed after Teva Pharmaceutical Industries Ltd. acquired Cephalon in 2011. Teva inherited Cephalon's armodafinil portfolio and its generic-settlement arrangements.

How did the Cephalon-Apotex settlement affect generic entry?

The settlement resolved the infringement dispute without a finding that Apotex's proposed product infringed a valid, enforceable patent. Public reports associated the settlement with a permitted generic-entry date in 2016, subject to the agreement's terms and regulatory approval.

Issue	Settlement effect
Immediate generic launch	Restricted
Patent validity	Not adjudicated
Patent enforceability	Not adjudicated
Apotex launch right	Deferred future entry
Settlement terms	Commercial terms not fully public
Case status	Dismissed after settlement

The settlement's business function was to convert uncertain litigation into a defined launch timetable. Cephalon retained the ability to sell Nuvigil without Apotex competition during the agreed period. Apotex received a path to market before the full expiration of every potentially relevant patent, assuming FDA approval and compliance with the agreement.

That structure is materially different from a judgment. A settlement date does not establish the actual patent expiration date, and it does not prove that the challenged patents would have survived an invalidity or noninfringement challenge.

Did Apotex win a Paragraph IV challenge?

No merits ruling awarded Apotex a Paragraph IV victory. The case terminated by settlement.

A Paragraph IV certification is an applicant's legal position, not a court determination. Apotex challenged the relevant patent protection, but the public resolution did not establish that the patents were invalid, unenforceable, or not infringed. Cephalon likewise did not obtain a final judgment confirming infringement.

The litigation therefore produced no binding precedent on:

• Claim construction.
• Obviousness.
• Written description.
• Enablement.
• Patent-term calculation.
• Infringement by Apotex's ANDA product.
• Induced infringement based on the generic label.
• Inequitable conduct.

For diligence purposes, the absence of a merits decision means patent strength must be assessed from the issued claims, prosecution history, Orange Book listings, subsequent litigation, and generic-entry behavior.

What was the Orange Book status of Nuvigil?

The Orange Book listed patents associated with Nuvigil and provided the regulatory mechanism for Cephalon's patent enforcement. Orange Book listing does not mean that FDA has independently validated patent validity or infringement. FDA generally relies on the sponsor's patent information for listing and does not adjudicate the substantive patent dispute.

The Nuvigil estate included patent coverage directed to the product's pharmaceutical composition and approved methods of use. The practical protection depended on the relationship between the listed claims and Apotex's ANDA formulation and labeling.

After a 30-month stay, FDA approval could still be blocked by an enforceable patent judgment or delayed by a settlement restriction. Once the agreed entry date passed, FDA approval depended on the ordinary ANDA requirements, including bioequivalence, manufacturing compliance, labeling, and any remaining exclusivity.

How strong was Cephalon's Nuvigil patent estate?

The estate had meaningful commercial strength but limited long-term durability once generic applicants began filing Paragraph IV challenges.

Strengths

• Nuvigil had a differentiated active ingredient relative to modafinil, even though the two products were closely related.
• Composition and formulation claims can be difficult to design around when they cover the active pharmaceutical ingredient in a required dosage form.
• The patents were listed in the Orange Book, allowing Cephalon to invoke the Hatch-Waxman litigation stay.
• Settlements deferred generic competition and protected near-term revenue.

Weaknesses

• Armodafinil's relationship to modafinil created prior-art and obviousness issues.
• Method-of-use patents could be vulnerable if the generic label omitted or carved out the patented indication.
• Continuation patents could face written-description, obviousness, and double-patenting challenges.
• Regulatory exclusivity was limited compared with a new chemical entity.
• Settlement-based protection did not resolve the underlying validity questions.

The estate was commercially effective because it delayed competition. The public docket does not support describing it as judicially validated.

What generic-entry risks existed after the settlement?

The primary risk was delayed but eventual erosion of Nuvigil sales. Generic armodafinil could enter through Apotex or other applicants after settlement restrictions expired and FDA approval was available.

Generic-entry scenario	Commercial consequence
Single authorized or settlement-approved generic	Moderate initial price pressure
Multiple ANDA approvals near the same date	Rapid erosion of branded volume and price
Authorized generic launch by the brand owner	Greater control over substitution economics
Formulation or labeling carve-out	Partial competition by indication
Additional Paragraph IV settlements	Staggered competition
Patent litigation loss	Earlier-than-planned generic entry

Armodafinil is an oral solid dosage product with no biologic comparability barrier. Biosimilar risk was therefore not relevant. The main competitive threats were ANDA applicants, authorized generics, and substitution under state pharmacy laws.

Which companies challenged Cephalon's armodafinil patents?

Apotex was one of the generic companies that challenged Cephalon's Nuvigil patent position. The wider armodafinil competitive field included major generic manufacturers that pursued ANDA approval or negotiated entry arrangements with Cephalon or Teva.

The market risk was cumulative. A settlement with one applicant could defer that applicant's entry while leaving other ANDA litigation active. Conversely, a coordinated series of settlements could establish a relatively predictable generic-entry date while avoiding a first adverse judgment against the patent estate.

What litigation status affects Nuvigil revenue exposure?

The Apotex case itself ended and no longer presented active trial risk. The remaining exposure was commercial:

1. The agreed entry date could accelerate generic competition relative to full patent expiry.
2. Other ANDA applicants could obtain earlier entry through separate litigation or settlements.
3. Multiple generic entrants could reduce prices faster than a single entrant.
4. Patent expiration or loss of enforceability could open the market to broad substitution.
5. Nuvigil revenue could decline before all listed patents expired if settlements permitted launch.

For valuation purposes, the relevant date is not only the nominal expiration date of the strongest patent. Analysts should model the earliest credible generic-entry date, the number of expected entrants, the possibility of authorized generic competition, and the degree of automatic pharmacy substitution.

How did Nuvigil compare with Provigil patent protection?

Nuvigil and Provigil were related but distinct commercial products.

Issue	Nuvigil	Provigil
Active ingredient	Armodafinil	Modafinil
Product type	Enantiomer-based follow-on product	Original modafinil product
Primary regulatory risk	Limited exclusivity and Paragraph IV ANDAs	Earlier and broader generic-modafinil pressure
Patent strategy	Composition, formulation, and use claims	Composition, manufacturing, formulation, and use claims
Generic pathway	Armodafinil ANDA	Modafinil ANDA
Biosimilar risk	None	None

Cephalon's commercial strategy relied on Nuvigil as a successor product while Provigil faced generic pressure. The legal protection for Nuvigil could delay armodafinil competition, but it did not prevent substitution between modafinil and armodafinil where prescribers and payers treated the products as therapeutically interchangeable.

Key Takeaways

• Cephalon Inc. v. Apotex Corp., No. 1:10-cv-00695, was a Delaware Hatch-Waxman case involving generic armodafinil and Nuvigil.
• Cephalon sued after Apotex filed a Paragraph IV certification against Nuvigil-related patents.
• The dispute settled and was dismissed without a trial or merits judgment.
• The settlement deferred Apotex's generic entry, reportedly to 2016, subject to regulatory approval and agreement terms.
• The case did not establish that Cephalon's patents were valid, enforceable, or infringed.
• Nuvigil's commercial protection depended more heavily on patents than on long-term FDA exclusivity.
• Generic and biosimilar risk should be separated: ANDA competition was material, while biosimilar competition was not applicable.
• The principal business risk was revenue erosion from one or more generic armodafinil entrants after the settlement-controlled entry period.

FAQs About Cephalon v. Apotex and Nuvigil Patents

Was Cephalon v. Apotex a patent-infringement trial?

No. The case ended by settlement and dismissal. The court did not issue a public merits ruling on infringement, validity, or enforceability.

What product did Apotex seek to market?

Apotex sought FDA approval for generic armodafinil tablets, the active ingredient in Nuvigil.

Did the settlement invalidate Nuvigil patents?

No. The settlement did not invalidate the asserted patents and did not establish that they would survive a final validity challenge.

Could Apotex launch before all Nuvigil patents expired?

Yes. A settlement can authorize entry before the latest patent expiration date. The permitted date depends on the agreement and FDA approval rather than solely on the nominal expiration date.

Was Nuvigil exposed to biosimilar competition?

No. Nuvigil is a small-molecule oral drug. Its direct competition came through ANDA-based generic armodafinil products, not the biosimilar pathway.

References

1. Cephalon Inc. v. Apotex Corp., No. 1:10-cv-00695, U.S. District Court for the District of Delaware. (2010-2011). Public docket record.

2. U.S. Food and Drug Administration. (2007). Nuvigil (armodafinil) approval history and prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,848,327: Pharmaceutical compositions and methods associated with armodafinil. USPTO.

5. Federal Trade Commission. (2013). Pay-for-delay: How drug company pay-offs cost consumers billions. FTC.

6. U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated new drug applications and patent certifications.